Purple Biotech presents new preclinical IM1240 cancer data at EACR 2026 congress
PPBT•Preclinical IM1240 data presented at EACR 2026
Purple Biotech highlighted new preclinical data on cancer candidate IM1240, already presented at the EACR 2026 Annual Congress.
The results supported a differentiated anti-tumor profile, favorable safety and pharmacokinetics, and a broad therapeutic window.
